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culated for a one year follow-up. Adherence was measured using proportion of
days covered (PDC), where a PDC80 was considered adherent. Multi-variable lin-
ear regressionwas used to examine the relationships between cost and adherence,
controlling for patient demographics (age, gender, and job type) and Charlson co-
morbidity score. RESULTS:Among the 4978 individuals included in the study, the
average adherence to oral hypoglycemic agents was 72.7%, and 56.6% (N2820)
of the study population had a PDC80. The mean total medical/pharmacy costs
were similar for both the adherent and the non-adherent. Individuals who were
adherent to their diabetes medications, however, had significantly lower short-
term disability costs ($1161/year) than did the non-adherent ($1840/year).
CONCLUSIONS: In general, diabetes patients who adhered to their treatment reg-
imen had much lower short-term disability costs when compared to the non-
adherent. This result carries special implications for employers concernedwith the
total costs associated with diabetes in their employee populations.
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OBJECTIVES: To assess adherence and persistence to OAD medications in the pe-
diatric population and to determine how adherence and persistence differ by age,
gender and race in the study population. METHODS: A retrospective cohort anal-
ysis of the Texas Medicaid prescription claims database. The study included pedi-
atric subjects (10-18 years) with type 2 diabeteswhohadOADmedications between
January 2006 and December 2009. Index date was defined as the date subjects had
their first OAD medication between January 1, 2006 and December 31, 2009. Pre-
scription claims were analyzed over a 6 month pre-index period through a 12-
month post-index period. Adherence was measured using the medication posses-
sion ratio (MPR). RESULTS: A total of 3,109 subjects met inclusion criteria. The
overall mean MPR SD was 44.69%  27.06. Adherence differed by gender
(p0.0001); race (p0.0001); and age category (p0.0001). Males had higher mean
MPR SD (47.47  27.42) compared to females (43.29  26.78). In addition, mean
MPR for whites (50.04 29.65) was significantly higher compared to blacks (44.24
26.16) and Hispanics (42.50  26.10). Subjects  12 years of age had significantly
highermeanMPR (48.82 27.27) compared to those in older age categories. Logistic
regression analysis revealed that age (continuous) was significantly related
(OR0.91; 95% CI0.87-0.95) to being adherent (MPR80%). Males were 25% (OR
1.25; 95%CI1.02-1.53; p0.034) more likely to be adherent (MPR80%) compared
to females andwhites were twicemore likely to be adherent (MPR80%) compared
to Hispanics (OR2.02; 95%CI1.54-2.66; p0.0012). The overall mean days to non-
persistence ( SD)was 108 days ( 86). Persistencewas significantly and negatively
associatedwith age (p 0.0001). Among the covariates,white racewas significantly
related to longer persistence. CONCLUSIONS: Adherence and persistence to OAD
medications in the study population is generally suboptimal.
PDB69
THE IMPACT OF NOCTURNAL HYPOGLYCEMIC EVENTS ON FUNCTIONING,
WELL-BEING AND DIABETES MANAGEMENT
Brod M1, Wolden M2, Pohlman B1, Christensen T3
1The Brod Group, Mill Valley, CA, USA, 2Novo Nordisk A/S, Søborg, Denmark, 3Novo Nordisk
A/S, Virum, Denmark
OBJECTIVES: Non-severe Nocturnal Hypoglycemic Events (NSNHEs) are hypogly-
cemic events that occur during sleep but don’t require medical assistance from
another individual. Impacts NSNHEs may have on are rarely studied and little is
known about how NSNHEs may affect patient functioning, well-being, and diabe-
tes management. METHODS: Nine focus groups were held in four countries
(France, Germany, United Kingdom, US) with diabetics who had experienced a
NSNHE within the previous month. Groups were audio-taped and analyzed the-
matically according to grounded theory principles of concept elicitation. RESULTS:
78 people with diabetes participated in the focus groups (53% female, 69% Type 2
diabetes, 65% insulin dependent). The average incident rate of NSNHEs was 4.0 per
month (range: 1-22.5). NSNHEs were thought to be more difficult to predict, under-
stand, or manage and created more worry than day time events. Thematic satura-
tion was reached after the 7th focus group. Major themes for both diabetes types,
defined as those that occurred in more than 5% of statements, were Next Day
Effects(17.3%), Symptoms (14.3%), Sleep Impacts (11.3%), Social Impacts (8.5%), Cor-
rective Action (8.5%), Practical Management (8.5%), Feelings about NSNHEs
(5.5%)and Work Impacts (5.5%). The negative effects of these areas of impacts
appear to be caused by the unique confluence of sleep disruption with the physi-
ologic effects of fluctuating blood sugars in the night and throughout the next day.
The following day 11% of respondents reported adjusting their insulin dose, 6%
monitored their blood sugars more frequently and 6% stated that they run their
sugars high before bedtime as a strategy for avoiding NSNHEs. CONCLUSIONS:
Both Type 1 and Type 2, insulin dependent and not, patients, experience NSNHEs
and the range of impact on these patients is wide with a majority of participants
experiencing strong impactswhich limit their daily functioning andwell-being and
affect their diabetes management strategies.
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OBJECTIVES: To assess health utilities and examine factors affecting health utili-
ties among patientswith type 2 diabetesmellitus (T2DM) in China.METHODS:Data
were obtained from a cross-sectional survey of T2DM patients in outpatient set-
tings from October to December, 2011 in Beijing and Tianjin. Eligible patients were
18 years, had a diagnosis of T2DM 1 year and received 1 year anti-diabetic
treatment. Health utility was measured using The Chinese version of EQ-5D. The
EQ-5D index score and visual analog scale (VAS) score were calculated for all T2DM
patients and subgroups defined by fasting blood glucose control (FBG8 mmol/L)
and complications. Multivariate linear regressions were conducted to assess fac-
tors associated with health utilities such as patient demographics, glucose control,
complications, and lifestyle variables. RESULTS: A total of 588 patients were in-
cluded with 54.9% female, mean age of 63.3 years and mean disease duration of 11.3
years. About 64.5% patients had FBG control. Most patients (94.9%) had1 complica-
tion: macrovascular complications (50.9%), retinopathy (59.1%), nephropathy (28.6%),
neuropathy (52.3%). Mean EQ-5D and VAS scores for all patients were 0.78 and 64,
respectively. Mean EQ-5D score was higher among patients with FBG control versus
those without (0.80 vs. 0.75, p0.003). Patients with macrovascular complications,
retinopathy, nephropathy and neuropathy had significantly lower EQ-5D score com-
pared to those without the corresponding complications (0.73 vs. 0.82, 0.75 vs. 0.83,
0.74 vs. 0.80, and 0.73 vs. 0.84, respectively; all P0.001). Similar results were observed
for EQ-VAS in these comparisons. Macrovascular complications and somemicrovas-
cular complications (e.g., nephropathy and neuropathy) were negatively associated
with health utilities while education and exercise were positively associated with
health utilities. CONCLUSIONS: Compared to the general Chinese population (EQ-
VAS of 80), patients with T2DM have impaired quality of life. Factors affecting
health utilities may include complications, education and exercise.
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OBJECTIVES:We sought to assess the disutility associated with diabetes after kid-
ney transplant. METHODS: We enrolled 233 kidney transplant recipients aged
18-74 years (response rate 79%) from a Midwestern hospital outpatient department.
Recipients with multiple or multi-organ transplants, those with laboratory evidence
that suggests acute cellular damage (Creatinine-Kinase 200 U/L), or a diagnosis of
acute renal failure or acute rejection were excluded from the analysis (n33). Partici-
pants HRQOLwere evaluated using the Euro-QoL-5 Dimension (EQ-5D), Health Utility
IndexMark III (HUI-III), and the Short Form-6D (SF-6D) whichwas calculated from the
generic section (SF-12) of the Kidney Disease Quality of Life 36 (KDQOL-36). We esti-
mated health utilities associated with diabetes using General Linear Modeling after
adjusting for demographic, socio-economic, and clinical characteristics. RESULTS:
The adjusted Health disutilities associated to diabetes were clinically and statisti-
cally significant: EQ-5D (	0.05; p0.01), HUI-III (	0.09; p0.01), and SF-6D
(	0.04, p0.01). There was no difference between diabetic patients with good gly-
cemic control (mean serum glucose 126mg/dL in the 3 months prior to enrollment)
and patients with poor glycemic control. CONCLUSIONS: Among kidney transplant
patients between the ages of 18 to 74, non-diabetics have significantly higher
HRQOL scores on the EQ-5D, HUI-III, and SF-6D compared to diabetic patients.
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OBJECTIVES: There is evidence in the literature linking weight gain on anti-diabetic
medication to impact on psychosocial well-being and non-compliance in type 2 dia-
betes (T2D). Due to the lack of data on the impact of weight loss and the imminent
introduction of a new class of oral agents (SGLT2 inhibitors) with demonstrated
weight-loss properties, this studywas designed to compare the impact of weight gain
and weight loss on utilities among Canadian T2D patients.METHODS: Health states
included a T2D base-case health state and six additional weight change health states
(base-case 3%, 5%, and 7% weight change relative to current weight). Utilities
wereelicitedusing timetrade-off techniques. Enrollment requirements included:hav-
ingT2D for at least twoyears, adequate control onantidiabeticmedication, not receiv-
ing insulin, and not enrolled in a T2D clinical trial. RESULTS: Among 96 respondents
(mean age 55 years; 51%male; mean bodymass index (BMI) 32 kg/m2) 84% expressed
a desire to lose weight. The mean utility (standard error (SE)) for the base-case T2D
health state was 0.911 (0.013). The utility decreased to 0.907 (0.013), 0.865 (0.014) and
0.806 (0.017) for the 3%, 5% and 7% weight gain health states, respectively, and in-
creased to 0.923 (0.012), 0.940 (0.011) and0.949 (0.010) for the 3%, 5%and7%weight loss
health states, respectively. Linear mixed models indicated that a change in weight
leading to a one unit increase and decrease in BMI had significant effects (SE) on
utilities of -0.0472 (0.005) and 0.0171 (0.003), respectively. CONCLUSIONS: We ob-
served a dose-response relationship betweenweight change and patient-elicited util-
ities in T2D health states with weight gain having a stronger effect than weight loss.
Theweight-loss properties of SGLT2 inhibitorsmay improveutilitieswhile preventing
the disutility associated with weight gain, which may positively impact treatment
compliance and health outcomes.
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